 MONMOUTH JUNCTION, N.J., May 11, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a critical care leader commercializing its CytoSorb and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency DHA Sequential Phase II Small Business Innovation Research SBIR contract, valued at 1,499,987 over 28 months, to advance development of the KontrolTM platform for the treatment of severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine. 